



Séminaire de Modèles Industriels 2012

Jeudi 23 février

10h – 12h Salle des Actes

- **Aeterna-Zentaris.**

Aeterna-Zentaris est une entreprise de développement de produits au stade clinique avancé en oncologie, dont les activités de recherche sont axées sur des traitements potentiels contre plusieurs types de cancer notamment : colorectal, myélome multiple, endomètre, ovaires, prostate et vessie. L'approche novatrice de la Société dite « médecine personnalisée » vise à développer des traitements adaptés à la condition spécifique du patient et aux besoins médicaux non comblés. Le vaste portefeuille d'Aeterna Zentaris repose sur sa propre unité de découverte de produits, lui permettant ainsi un accès constant et à long terme, à des options thérapeutiques de pointe.

- **Biotest.**

Biotest is a company specializing in innovative hematology and immunology products with the holistic approach of a global pharmaceutical, diagnostics and biotherapeutics group. Its approximately 2,000 employees develop, manufacture and sell medicinal products for the treatment of blood and immune diseases as well as products for the hygiene monitoring of air and work surfaces. The most important starting material for our pharmaceutical products is human blood plasma which we process into effective and highly pure medicinal products in one of the world's most modern production facilities in Europe. One of our highest priority research projects is the development of monoclonal antibodies, active substances produced by biotechnological techniques, which will open up new prospects in the treatment of rheumatism, leukaemia and other autoimmune diseases.

13h30 – 15h30 Amphi Pauling

- **Ipsen.**

Ipsen est un groupe pharmaceutique de spécialité qui a affiché en 2010 des ventes supérieures à 1,1 milliard d'euros. L'ambition d'Ipsen est de devenir un leader dans le traitement des maladies invalidantes. Sa stratégie de développement s'appuie sur 4 franchises : neurologie / Dysport®, endocrinologie / Somatuline®, uro-oncologie / Décapeptyl® et l'hémophilie. Par ailleurs, le Groupe a une politique active de partenariats. La R&D est spécialisée dans des plateformes différenciées et innovantes en peptides et en toxines au service des patients. En 2010, les dépenses de R&D ont atteint plus de 220 millions d'euros, soit plus de 20 % du chiffre d'affaires. Le Groupe rassemble près de 4 500 collaborateurs dans le monde.

- **Lundbeck.**

Lundbeck is a global pharmaceutical company conducting research into, developing, manufacturing, marketing, selling and distributing pharmaceuticals for the treatment of disorders in the central nervous system (CNS), including depression, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, epilepsy and insomnia. Lundbeck employs 5.900 people worldwide, 2.000 of whom are based in Denmark. Lundbeck has employees in 57 countries, and its products are registered in more than 100 countries. Lundbeck has production facilities in Italy, France, Mexico and Denmark and research centers in Denmark and the USA.

Pause

16h – 18h Amphi Pauling

- **Merck-Serono.**

Merck Serono began when the German chemical and pharmaceutical group Merck acquired Serono, the Swiss-based biotechnology leader, integrating two companies with a total of over 400 years of experience in drug-making. Merck KGaA has a history dating back to 1668, when Friedrich Jacob Merck acquired the Engel Apotheke ("Angel pharmacy") in Darmstadt, Germany. Serono's roots as a pioneer in the use of recombinant DNA technology go back to Italy in the early 1900's.

- **Parexel.**

Parexel is a leading global bio/pharmaceutical services organization that helps clients expedite time-to-market through our development and launch services. These include a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialization services. As an innovator in the biopharmaceutical services industry, PAREXEL continues to create new models of operating excellence and best practices to help our industry partners address key product development challenges.



Séminaire de Modèles Industriels 2012

Vendredi 24 février

9h30 – 13h **Salle des Actes**

- **Stallergene.**

Stallergenes est un laboratoire biopharmaceutique européen spécialisé dans le traitement par immunothérapie allergénique de l'allergie respiratoire sévère. Leader mondial dans l'immunothérapie sublinguale dont il est à l'origine, Stallergenes est engagé depuis 2003 dans le programme de développement Stalair®, qui constitue une nouvelle classe thérapeutique et couvre 80% des allergies respiratoires : les comprimés sublinguaux d'immunothérapie allergénique enregistrés et aux propriétés documentées selon les règles de l'EBM* (Evidence Based Medicine).

- **Teva.**

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company that develops, produces and markets generic drugs covering all major treatment categories. It also produces and supplies active pharmaceutical ingredients to the drug manufacturing industry worldwide. The company offers its products in two categories: Generic Products and Branded Products. The Branded Products category includes two innovative products that the company has developed: Copaxone, for the treatment of multiple sclerosis, and Azilect, for the treatment of Parkinson's disease, respiratory products, women's health products and biopharmaceuticals and biogenerics. Its global presence covers North America, Europe, Latin America, Asia and Israel. Currently, the company has direct operations in more than 60 countries, including 38 finished dosage pharmaceutical manufacturing sites in 17 countries, 15 generic R&D centers operating mostly within certain manufacturing sites and 21 API manufacturing sites around the world. It was founded in 1901 and is headquartered in Petach Tikva, Israel.

Pause

- **UCB.**

UCB headquartered in Brussels, Belgium, is a global biopharma company with a team of over 8500 employees, a strong market presence in more than 40 countries, € 3.2 billion in revenue (2010) and numerous strategic partnerships across the industry. Already the leader in epilepsy, UCB is committed to providing novel solutions for people with severe conditions such as Parkinson's disease, rheumatoid arthritis, restless legs syndrome...